Oscient reiterated by JMP at strong buy

Oscient Pharmaceuticals Corp. was reiterated by JMP Securities analyst Adam Cutler at a strong buy rating with a price target on the stock of $6 per share on good weekly prescription data from NDC Health for its Factive and Testim products. Oscient shares Tuesday were up $0.13, or 5.99%, at $2.30 on volume of 821,537 shares versus the three-month running average of 723,009 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.